But the copycat craze is showing signs of losing steam. Most crypto treasury companies are lossmaking or simply shell vehicles, with executives’ and investors’ belief in the value of their tokens being the sole driving force for share price gains.
Biotech company 180 Life Sciences changed its name to ETHZilla last month and began loading up on ether tokens. Its shares have sunk 76 per cent from their August peak and the company is valued at $416mn, despite holding about $460mn worth of ether.
Last week, ETHZilla raised $80mn in debt collateralised against its ether holdings from Cumberland DRW, the crypto arm of
Don Wilson’s market maker DRW. It will use the funds to purchase its own shares as part of its $250mn buyback plan.